Missouri Medicaid

Does Missouri Medicaid cover Wegovy?

Quick answer · Weight Loss

Missouri Medicaid covers Wegovy for weight loss with prior authorization on Medicaid.

  • Medicaid: Covered with requirements. BMI of 30 or higher

Last verified June 3, 2026. Policy effective January 29, 2026. Source: policy-311.html. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What Missouri Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, dyslipidemia, OSA, pre-diabetes, T2DM, prior_MI, prior_stroke, and symptomatic_PAD)
  • BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Pediatric (age 12–17): BMI-based

All of:

  • Participant is aged 12–17 years
  • Documented baseline BMI >= 95th percentile standardized for age and sex
  • Medical necessity documented for using Wegovy instead of preferred agent (Zepbound)

Adult (age >= 18): BMI >= 30

All of:

  • Participant is aged >= 18 years
  • Documented baseline BMI >= 30 kg/m2
  • Medical necessity documented for using Wegovy instead of preferred agent (Zepbound)

Adult (age >= 18): BMI >= 27 with comorbidity

All of:

  • Participant is aged >= 18 years
  • Documented baseline BMI >= 27 kg/m2
  • Medical necessity documented for using Wegovy instead of preferred agent (Zepbound)

Plus any one of:

  • Hypertension
  • Dyslipidemia
  • Obstructive sleep apnea
  • Pre-diabetes (A1C 5.7–6.4%, fasting glucose 100–125 mg/dL, or 2-hr OGTT 140–199 mg/dL)
  • Previous myocardial infarction
  • Previous stroke
  • Symptomatic peripheral arterial disease (intermittent claudication with ABI < 0.85, peripheral arterial revascularization, or amputation due to ASCVD)
  • Type 2 diabetes mellitus

Adult (age >= 18): MASH with F2 or F3 fibrosis (general weight loss pathway)

All of:

  • Participant is aged >= 18 years
  • Recent liver biopsy or noninvasive techniques confirming MASH with F2 or F3 fibrosis
  • Medical necessity documented for using Wegovy instead of preferred agent (Zepbound)

Continuation: Documented compliance with current preferred agent therapy

All of:

  • Documented compliance to current preferred agent therapy

Concurrent antipsychotic therapy

All of:

  • Documented concurrent therapy with antipsychotic therapy

Documentation to bring

  • Documentation of medical necessity explaining why preferred agent (Zepbound) cannot be utilized
  • Participant age documentation (>= 12 years)
  • For ages 12–17: Documented baseline BMI >= 95th percentile standardized for age and sex
  • For ages >= 18 with BMI >= 30: Documented baseline BMI >= 30 kg/m2
  • For ages >= 18 with BMI >= 27: Documented baseline BMI >= 27 kg/m2 AND documentation of at least one qualifying comorbidity
  • For MASH pathway: Recent liver biopsy or noninvasive techniques confirming MASH with F2 or F3 fibrosis

Quantity limits

  • 0.25 mg/0.5 mL pen, 0.5 mg/0.5 mL pen, 1 mg/0.5 mL pen — 2 mL per 28 days
  • 1.7 mg/0.75 mL pen, 2.4 mg/0.75 mL pen — 3 mL per 28 days

Approval and renewal

  • To renew, the plan looks for staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Concurrent therapy with another GLP-1 receptor agonist
  • Unable to complete titration/dose escalation to at least 1.7 mg/dose within 6 months of beginning therapy

Policy note: Wegovy is a non-preferred agent; Zepbound is preferred. Medical necessity for non-preferred use required. Initial approval is for 4 weeks only; subsequent approvals required for each dose during titration until maintenance dose of at least 1.7 mg is achieved. An additional 4 weeks per dose in the titration process may be approved one time with documentation of intolerable adverse effects during dose escalation. Default approval period (once maintenance reached) is 1 year 90 days. This weight_loss entry covers the general BMI-based obesity indication; the CV risk reduction and MASH indications for Wegovy are captured in separate entries. For the weight_loss indication, diabetes is NOT excluded (T2DM is listed as a qualifying comorbidity for the BMI >= 27 pathway).

Policy effective January 29, 2026 · verified June 3, 2026 · source: policy-311.html

Wegovy for Heart Disease Risk Reduction

What Missouri Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 45 and older
  • BMI of 27 or higher
  • A1C no higher than 6.4%
  • Established cardiovascular disease (MI, stroke, and symptomatic_PAD)
  • On guideline-directed medical therapy (cardiovascular disease pharmaceutical therapy (unspecified))
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction (MACE) — Wegovy only

All of:

  • Wegovy (non-preferred) — medical necessity for non-preferred use documented
  • Participant is aged >= 45 years
  • Documented baseline BMI >= 27 kg/m2
  • Lack of diabetes mellitus diagnosis in the past 2 years
  • Recent A1C < 6.5 within the past 3 months confirming absence of diabetes diagnosis
  • Lack of any history of anti-diabetic pharmaceutical therapy in the past 2 years
  • Documentation of current pharmaceutical therapy for cardiovascular disease

Plus any one of:

  • Documented diagnosis of myocardial infarction
  • Documented diagnosis of stroke
  • Symptomatic peripheral arterial disease — intermittent claudication with ABI < 0.85 (at rest), peripheral arterial revascularization procedure, or amputation due to ASCVD

Documentation to bring

  • Documentation of medical necessity for using Wegovy instead of preferred agent (Zepbound)
  • Participant age documentation (>= 45 years)
  • Documented baseline BMI >= 27 kg/m2
  • Documentation confirming no diabetes mellitus diagnosis in the past 2 years
  • Recent A1C < 6.5 within the past 3 months
  • Documentation confirming no anti-diabetic pharmaceutical therapy in the past 2 years
  • Documented diagnosis of qualifying CV event: myocardial infarction, stroke, or symptomatic PAD (with supporting evidence: ABI < 0.85, revascularization procedure, or amputation due to ASCVD)
  • Documentation of current pharmaceutical therapy for cardiovascular disease

Quantity limits

  • 0.25 mg/0.5 mL pen, 0.5 mg/0.5 mL pen, 1 mg/0.5 mL pen — 2 mL per 28 days
  • 1.7 mg/0.75 mL pen, 2.4 mg/0.75 mL pen — 3 mL per 28 days

Approval and renewal

  • To renew, the plan looks for staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Concurrent therapy with another GLP-1 receptor agonist
  • Unable to complete titration/dose escalation to at least 1.7 mg/dose within 6 months of beginning therapy
  • Diabetes mellitus diagnosis within past 2 years
  • Any history of anti-diabetic pharmaceutical therapy in past 2 years
  • A1C >= 6.5 on recent lab

Policy note: This is a Wegovy-specific pathway. Strictly requires absence of diabetes: no diabetes diagnosis in the past 2 years, no anti-diabetic pharmaceutical therapy in the past 2 years, and recent A1C < 6.5 (within 3 months). CVD pharma therapy is required but not specified beyond 'pharmaceutical therapy for cardiovascular disease.' Titration rules same as Wegovy weight_loss: initial approval 4 weeks, per-dose approvals during titration, must reach maintenance dose of at least 1.7 mg/dose within 6 months.

Policy effective January 29, 2026 · verified June 3, 2026 · source: policy-311.html

Wegovy for Liver Disease (MASH)

What Missouri Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by liver_biopsy and noninvasive_techniques, fibrosis stage F2 to F3
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

MASH with F2 or F3 fibrosis — Wegovy only

All of:

  • Wegovy (non-preferred) — medical necessity for non-preferred use documented
  • Participant is aged >= 18 years
  • Recent liver biopsy or noninvasive techniques confirming MASH with F2 or F3 fibrosis
  • Documented current liver function tests (LFTs)
  • Prescribed by or in consultation with a gastroenterologist, hepatologist, or other specialist in the treated disease state
  • Lack of diabetes mellitus diagnosis in the past 2 years
  • Recent A1C < 6.5 within the past 3 months confirming absence of diabetes diagnosis
  • Lack of any history of anti-diabetic pharmaceutical therapy in the past 2 years

Documentation to bring

  • Documentation of medical necessity for using Wegovy instead of preferred agent (Zepbound)
  • Participant age documentation (>= 18 years)
  • Recent liver biopsy or noninvasive techniques confirming MASH diagnosis with F2 or F3 fibrosis
  • Documented current liver function tests (LFTs)
  • Prescription from or documentation of consultation with a gastroenterologist, hepatologist, or other specialist in the treated disease state
  • Documentation confirming no diabetes mellitus diagnosis in the past 2 years
  • Recent A1C < 6.5 within the past 3 months
  • Documentation confirming no anti-diabetic pharmaceutical therapy in the past 2 years

Quantity limits

  • 0.25 mg/0.5 mL pen, 0.5 mg/0.5 mL pen, 1 mg/0.5 mL pen — 2 mL per 28 days
  • 1.7 mg/0.75 mL pen, 2.4 mg/0.75 mL pen — 3 mL per 28 days

Approval and renewal

  • To renew, the plan looks for staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Concurrent therapy with another GLP-1 receptor agonist
  • Unable to complete titration/dose escalation to at least 1.7 mg/dose within 6 months of beginning therapy
  • Cirrhotic MASH (policy states 'noncirrhotic' MASH)
  • Diabetes mellitus diagnosis within past 2 years
  • Any history of anti-diabetic pharmaceutical therapy in past 2 years
  • A1C >= 6.5 on recent lab

Policy note: This is a Wegovy-specific MASH pathway. The policy specifies 'noncirrhotic' MASH. The MASH confirmation methods are described as 'recent liver biopsy or noninvasive techniques' — specific noninvasive methods (e.g., FIB-4, FibroScan, MRE, ELF) are not enumerated. No explicit lookback period stated for biopsy or noninvasive tests ('recent' used without definition). Titration rules same as other Wegovy indications. The diabetes exclusion criteria (no DM diagnosis in past 2 years, no anti-diabetic therapy in past 2 years, A1C < 6.5 within 3 months) apply to all Wegovy-specific pathways per the document structure. Specialist requirement: prescribed by or in consultation with a gastroenterologist, hepatologist, or other specialist.

Policy effective January 29, 2026 · verified June 3, 2026 · source: policy-311.html

Why Wegovy requests get denied by Missouri Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. Prescriber isn't the specialist the plan requires.

Frequently asked questions

Does Missouri Medicaid cover Wegovy?
Missouri Medicaid covers Wegovy for weight loss with prior authorization on Medicaid.
What BMI do you need for Wegovy under Missouri Medicaid?
For weight loss on Medicaid plans, Missouri Medicaid requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
What does Missouri Medicaid require to renew Wegovy?
Staying on a maintenance dose of at least 1.7 mg.
How current is this information?
This page reflects Missouri Medicaid's written policy as of January 29, 2026, last verified against the source document on June 3, 2026.

Other medications under Missouri Medicaid

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Missouri Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.